聚乙二醇化赛妥珠单抗用于中度至重度类风湿关节炎异质性患者群体。
Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.
作者信息
Soriano Enrique R, Dellepiane Analia, Salvatierra Gabriela, Benítez Cristian Alejandro, Salinas Rodrigo Garcia, Baruzzo Carlos
机构信息
Rheumatology Unit, Hospital Italiano de Buenos Aires & Instituto Universitario Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
CEMEC Casilda, Santa Fe, Argentina.
出版信息
Future Sci OA. 2018 Feb 15;4(4):FSO289. doi: 10.4155/fsoa-2017-0149. eCollection 2018 Apr.
AIM
To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting.
MATERIALS & METHODS: Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed with Disease Activity Score of 28 joints, European Ligue Against Rheumatism criteria and Simplified Disease Activity Index. Predictors of response were analyzed with binary logistic regression models.
RESULTS
Statistically significant decreases in tender and swollen joint counts, laboratory parameters and use of corticosteroids and disease-modifying antirheumatic drugs were found. Disease activity also significantly diminished. Higher Disease Activity Score of 28 joints at baseline was the main predictor of response. No severe adverse events were reported.
CONCLUSION
Certolizumab was effective and well tolerated, particularly in the subpopulation with higher inflammatory burden at baseline.
目的
确定聚乙二醇化赛妥珠单抗在实际临床环境中治疗类风湿关节炎的疗效和安全性。
材料与方法
对开始使用聚乙二醇化赛妥珠单抗治疗的中重度类风湿关节炎患者进行了12周的随访。采用28个关节疾病活动评分、欧洲抗风湿病联盟标准和简化疾病活动指数评估反应情况。使用二元逻辑回归模型分析反应的预测因素。
结果
发现压痛和肿胀关节计数、实验室参数以及皮质类固醇和改善病情抗风湿药的使用在统计学上有显著下降。疾病活动度也显著降低。基线时较高的28个关节疾病活动评分是反应的主要预测因素。未报告严重不良事件。
结论
聚乙二醇化赛妥珠单抗有效且耐受性良好，特别是在基线时炎症负担较高的亚组中。
Zotero 插件